Literature DB >> 10779377

Octamer transcription factor-1 enhances hepatic nuclear factor-1alpha-mediated activation of the human UDP glucuronosyltransferase 2B7 promoter.

Y Ishii1, A J Hansen, P I Mackenzie.   

Abstract

The human UDP glucuronosyltransferase, UGT2B7, is expressed in the liver and gastrointestinal tract, where it catalyzes the glucuronidation of steroids and bile acids. In this study, the UGT2B7 gene was isolated and its proximal promoter was analyzed. The UGT2B7 gene consists of 6 exons and extends over 16 kilobases (kb). It does not contain a canonical TATA box but has a region (-2 to -40) adjacent to the transcription start site that binds nuclear proteins. This region contains a consensus hepatic nuclear factor-1alpha (HNF1alpha)-binding site and an overlapping AT-rich segment. Varying lengths of the UGT2B7 gene promoter, with and without these sites, were fused to the firefly luciferase reporter gene and transfected into HepG2 cells. UGT2B7 promoter activity with the HNF1/AT-rich element was stimulated by cotransfection with HNF1alpha. Additional activation was observed when HNF1alpha and octamer transcription factor-1 (Oct-1) were cotransfected simultaneously. However, Oct-1 alone did not stimulate promoter activity and did not bind to the promoter in the absence of HNF1alpha. Deletion of the HNF1/AT-rich region, or mutations in this region, abolished UGT2B7 gene promoter activity and prevented HNF1alpha-mediated increases in promoter activity. The presence of HNF1alpha and octamer transcription factor-1 (Oct-1) in the protein complex that bound to the HNF1/AT-rich region was demonstrated by gel shift analyses with antibodies specific to HNF1alpha and Oct-1 protein. These results strongly suggest that the liver-enriched factor HNF1alpha binds to, and activates, the UGT2B7 gene promoter and that the ubiquitous transcription factor, Oct-1, enhances this activation by directly interacting with HNF1alpha. This interaction between HNF1alpha and Oct-1 may fine-tune UGT2B7 expression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10779377

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  10 in total

1.  UGT2B gene expression analysis in multiple tobacco carcinogen-targeted tissues.

Authors:  Nathan R Jones; Philip Lazarus
Journal:  Drug Metab Dispos       Date:  2014-01-23       Impact factor: 3.922

2.  Upregulation of UGT2B4 Expression by 3'-Phosphoadenosine-5'-Phosphosulfate Synthase Knockdown: Implications for Coordinated Control of Bile Acid Conjugation.

Authors:  Kathleen G Barrett; Hailin Fang; Daniela Cukovic; Alan A Dombkowski; Thomas A Kocarek; Melissa Runge-Morris
Journal:  Drug Metab Dispos       Date:  2015-05-06       Impact factor: 3.922

3.  Activity and expression of various isoforms of uridine diphosphate glucuronosyltransferase are differentially regulated during hepatic regeneration in rats.

Authors:  Hui Tian; Junhai Ou; Stephen C Strom; Raman Venkataramanan
Journal:  Pharm Res       Date:  2005-10-21       Impact factor: 4.200

4.  Spectrum of HNF1A somatic mutations in hepatocellular adenoma differs from that in patients with MODY3 and suggests genotoxic damage.

Authors:  Emmanuelle Jeannot; Lucille Mellottee; Paulette Bioulac-Sage; Charles Balabaud; Jean-Yves Scoazec; Jeanne Tran Van Nhieu; Yannick Bacq; Sophie Michalak; David Buob; Pierre Laurent-Puig; Ivan Rusyn; Jessica Zucman-Rossi
Journal:  Diabetes       Date:  2010-04-14       Impact factor: 9.461

5.  Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients.

Authors:  Natalia Sutiman; Joanne Siok Liu Lim; Thomas E Muerdter; Onkar Singh; Yin Bun Cheung; Raymond Chee Hui Ng; Yoon Sim Yap; Nan Soon Wong; Peter Cher Siang Ang; Rebecca Dent; Werner Schroth; Matthias Schwab; Chiea Chuen Khor; Balram Chowbay
Journal:  Clin Pharmacokinet       Date:  2016-10       Impact factor: 6.447

6.  A pharmacogenetics study of the human glucuronosyltransferase UGT1A4.

Authors:  Marie-Odile Benoit-Biancamano; Jean-Philippe Adam; Olivier Bernard; Michael H Court; Marie-Hélène Leblanc; Patrick Caron; Chantal Guillemette
Journal:  Pharmacogenet Genomics       Date:  2009-12       Impact factor: 2.089

7.  Factors that influence the pharmacokinetics of lamotrigine in Japanese patients with epilepsy.

Authors:  Kazuyuki Inoue; Yoshiaki Yamamoto; Eri Suzuki; Toshiki Takahashi; Akiko Umemura; Yukitoshi Takahashi; Katsumi Imai; Yushi Inoue; Keita Hirai; Daiki Tsuji; Kunihiko Itoh
Journal:  Eur J Clin Pharmacol       Date:  2016-01-20       Impact factor: 2.953

8.  Hepatocyte nuclear factor 1 regulates the expression of the organic cation transporter 1 via binding to an evolutionary conserved region in intron 1 of the OCT1 gene.

Authors:  Valerie P O'Brien; Kristin Bokelmann; Jacqueline Ramírez; Karoline Jobst; Mark J Ratain; Jürgen Brockmöller; Mladen V Tzvetkov
Journal:  J Pharmacol Exp Ther       Date:  2013-08-06       Impact factor: 4.030

9.  Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells.

Authors:  Anne-Sophie Bélanger; Jelena Tojcic; Mario Harvey; Chantal Guillemette
Journal:  BMC Mol Biol       Date:  2010-01-22       Impact factor: 2.946

10.  Variants in mycophenolate and CMV antiviral drug pharmacokinetic and pharmacodynamic genes and leukopenia in heart transplant recipients.

Authors:  Kris Oreschak; Laura M Saba; Nicholas Rafaels; Amrut V Ambardekar; Kimberly M Deininger; RobertL PageII; JoAnn Lindenfeld; Christina L Aquilante
Journal:  J Heart Lung Transplant       Date:  2021-06-12       Impact factor: 13.569

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.